In T2 DM patients with a history of cardiovascular disease or cardiovascular risk factors, GLP-1 treatment significantly reduced the risk of the primary endpoint of cardiovascular death, non-fatal myocardial infarction, and stroke in diabetic patients (Ipp et al., 2017). Here, GCG is linked to myocardial infarction.